EBS - Emergent BioSolutions to amend credit agreement

2023-04-17 10:16:29 ET

• Emergent BioSolutions ( NYSE: EBS ) said on Monday it is set to amend an amended and restated credit agreement dated Feb. 14.
• The third amendment relates to the amendment of a waiver, as part of which the requisite lenders have agreed to extend the limited waiver of any defaults.
• The defaults can result from a violation of the financial covenants set forth in the credit agreement for the quarters ending Dec. 31, 2022, and March 31, 2023, or from going concern qualification or exception contained in financial statements for the year ended Dec. 31, 2022.
• The extended limited waiver expires if a default occurs under the existing credit agreement or on May 17.

For further details see: